RUNX1 and acute myeloid leukemia: These findings, together with other favorable properties of 7.4411, such as low molecular weight, a high ligand efficiency, and a non-complex chemical structure, suggest that 7.44 could serve as a lead structure to guide the development of structurally related compounds with increased binding affinity, improved bioavailability, and enhanced anti-leukemic effects to inhibit RUNX1/ETO oncogenic function in t(8;21) AML.